The National Institute for Health and Care Excellence (NICE) recommends that doctors prescribe SGLT-2 inhibitors along with metformin for most patients with newly diagnosed type 2 diabetes. SGLT-2 inhibitors are tablets that help the kidneys remove excess glucose from the body. Until now, these drugs were only recommended for patients with type 2 diabetes who also had chronic heart failure, confirmed atherosclerotic cardiovascular disease or a high risk of cardiovascular disease. According to the new recommendation from February 18, patients with type 2 diabetes diagnosed before the age of 40 should also be able to receive drugs from the class of GLP-1 receptor agonists, such as dulaglutide or tirzepatide, as an additional first-line treatment. This change represents an expansion of the use of SGLT-2 inhibitors as part of the initial treatment of type 2 diabetes.